NCT01800630View on ClinicalTrials.gov

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

March 31, 2016

Conditions
Advanced Solid MalignanciesMalignant Lymphomas
Interventions
DRUG

Gemcitabine HCl Oral Formulation

Trial Locations (3)

100

National Taiwan University Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

704

National Cheng Kung University Hospital, Tainan City

Sponsors

Lead Sponsor

InnoPharmax Inc.
All Listed Sponsors
lead

InnoPharmax Inc.

INDUSTRY